Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers

Abstract The kynurenine pathway (KP) is the main path for tryptophan metabolism, and it represents a multitude of potential sites for drug discovery in neuroscience, including pain, stroke, and epilepsy. L‐kynurenine (LKYN), the first active metabolite in the pathway, emerges to be a prodrug targeti...

Full description

Bibliographic Details
Main Authors: Mohammad Al‐Mahdi Al‐Karagholi, Jakob Møller Hansen, Dalia Abou‐Kassem, Anna Koldbro Hansted, Kumari Ubhayasekera, Jonas Bergquist, László Vécsei, Inger Jansen‐Olesen, Messoud Ashina
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Pharmacology Research & Perspectives
Subjects:
epilepsy
glutamat
kynurenic acid
migraine
stroke
Online Access:https://doi.org/10.1002/prp2.741

Internet

https://doi.org/10.1002/prp2.741

Similar Items